MX2024010009A - Formas de dosificacion oral de agonista de tr\03b2 vk2809 para el tratamiento de trastornos hepaticos y metodos de preparacion de las mismas. - Google Patents
Formas de dosificacion oral de agonista de tr\03b2 vk2809 para el tratamiento de trastornos hepaticos y metodos de preparacion de las mismas.Info
- Publication number
- MX2024010009A MX2024010009A MX2024010009A MX2024010009A MX2024010009A MX 2024010009 A MX2024010009 A MX 2024010009A MX 2024010009 A MX2024010009 A MX 2024010009A MX 2024010009 A MX2024010009 A MX 2024010009A MX 2024010009 A MX2024010009 A MX 2024010009A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage forms
- oral dosage
- trî2
- agonist
- preparing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311905P | 2022-02-18 | 2022-02-18 | |
| US202263312650P | 2022-02-22 | 2022-02-22 | |
| PCT/US2023/012935 WO2023158616A1 (en) | 2022-02-18 | 2023-02-13 | ORAL DOSAGE FORMS OF TRβ AGONIST VK2809 FOR THE TREATMENT OF LIVER DISORDERS AND METHODS OF PREPARING THE SAME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010009A true MX2024010009A (es) | 2024-08-22 |
Family
ID=87578867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010009A MX2024010009A (es) | 2022-02-18 | 2023-02-13 | Formas de dosificacion oral de agonista de tr\03b2 vk2809 para el tratamiento de trastornos hepaticos y metodos de preparacion de las mismas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250134913A1 (https=) |
| EP (1) | EP4479062A4 (https=) |
| JP (1) | JP2025505802A (https=) |
| KR (1) | KR20240149941A (https=) |
| CN (1) | CN119072316A (https=) |
| AU (1) | AU2023220955A1 (https=) |
| CA (1) | CA3251549A1 (https=) |
| MX (1) | MX2024010009A (https=) |
| WO (1) | WO2023158616A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| CN118615254A (zh) * | 2023-03-08 | 2024-09-10 | 甘莱制药有限公司 | 片剂及其制备方法与用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL372247A1 (en) * | 2002-02-01 | 2005-07-11 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| WO2007109605A2 (en) * | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| CN116942684A (zh) * | 2020-02-20 | 2023-10-27 | 甘莱制药有限公司 | 一种用于治疗脂肪性肝炎的药物组合物及其制备方法 |
| US11752161B2 (en) * | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
| JP7470204B2 (ja) * | 2020-03-27 | 2024-04-17 | ガンネックス ファーマ カンパニー リミテッド | 医薬組成物、その調製方法及び使用方法 |
| TW202315608A (zh) * | 2021-07-06 | 2023-04-16 | 中國大陸商甘萊製藥有限公司 | 用於治療肝臟疾病的聯合治療 |
-
2023
- 2023-02-13 WO PCT/US2023/012935 patent/WO2023158616A1/en not_active Ceased
- 2023-02-13 AU AU2023220955A patent/AU2023220955A1/en active Pending
- 2023-02-13 JP JP2024548635A patent/JP2025505802A/ja active Pending
- 2023-02-13 US US18/836,719 patent/US20250134913A1/en active Pending
- 2023-02-13 CN CN202380034572.9A patent/CN119072316A/zh active Pending
- 2023-02-13 CA CA3251549A patent/CA3251549A1/en active Pending
- 2023-02-13 EP EP23756790.4A patent/EP4479062A4/en active Pending
- 2023-02-13 KR KR1020247030354A patent/KR20240149941A/ko active Pending
- 2023-02-13 MX MX2024010009A patent/MX2024010009A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4479062A4 (en) | 2026-03-04 |
| JP2025505802A (ja) | 2025-02-28 |
| US20250134913A1 (en) | 2025-05-01 |
| KR20240149941A (ko) | 2024-10-15 |
| CA3251549A1 (en) | 2023-08-24 |
| EP4479062A1 (en) | 2024-12-25 |
| CN119072316A (zh) | 2024-12-03 |
| AU2023220955A1 (en) | 2024-08-15 |
| WO2023158616A1 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010009A (es) | Formas de dosificacion oral de agonista de tr\03b2 vk2809 para el tratamiento de trastornos hepaticos y metodos de preparacion de las mismas. | |
| CA2691667C (en) | Method for the production of a pharmaceutical containing tadalafil | |
| JP6530845B2 (ja) | イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物の安定化方法 | |
| NO340156B1 (no) | Fremgangsmåte for fremstilling av en fast, oralt administrerbar farmasøytisk sammensetning | |
| JP2005320354A5 (https=) | ||
| IL102777A (en) | Pharmaceutical combination formulation | |
| CA2447005A1 (en) | Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases | |
| RU2014131238A (ru) | Состав с отсроченным высвобождением для уменьшения частоты мочеиспускания и способ его применения | |
| US8758818B2 (en) | Oral tablet compositions of dexlansoprazole | |
| KR101895962B1 (ko) | 알리사르탄 이소프록실 고체 분산체 및 이를 포함하는 약제학적 조성물 | |
| JP2019514993A5 (https=) | ||
| KR20170009897A (ko) | 알리사르탄 이소프록실 고체 분산체 및 이의 약제학적 조성물 | |
| AU2015349896A1 (en) | Pharmaceutical bead formulations comprising dimethyl fumarate | |
| JP6618736B2 (ja) | ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法 | |
| KR20180097623A (ko) | 아프레밀라스트 서방형 제제 | |
| HRP20251276T1 (hr) | Postupak za kristalizaciju aktivnih farmaceutskih sastojaka | |
| CN101854921B (zh) | 用于口服施用ppi的药物制剂 | |
| EP2564832A1 (en) | Solid dosage form of HIV protease inhibitors | |
| JPH08301789A (ja) | 活性化合物の調節された放出性を有する製剤およびそれらの製造方法 | |
| EP3925601A1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
| CN107823166A (zh) | 一种利伐沙班片的制备方法 | |
| WO2025003956A1 (en) | High drug loading formulations of encorafenib | |
| CN114533690B (zh) | 含抗凝血药物西洛他唑的新制剂及其制备方法 | |
| JP2017523164A (ja) | コハク酸メトプロロールのカプセル剤形 | |
| CA2433915A1 (en) | Improved controlled release oral dosage form |